Skip to main content
TipRanks
Go Ultimate75% OFF

Theraclion SA (TCLIF) AI Stock Analysis

4 Followers
TCLIF

Theraclion SA

(Other OTC:TCLIF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Non-invasive therapeutic platformThe company’s non-invasive, image-guided ultrasound approach addresses procedures that would otherwise involve surgery, giving its technology a differentiated clinical proposition. A platform spanning thyroid and breast indications could support broader adoption and provide multiple avenues for commercial development over the next several quarters.
Negative Factors
Persistent unprofitabilityLosses across gross, operating, and net income indicate that the current revenue base does not support the company’s cost structure. Persistent unprofitability can consume capital, restrict strategic flexibility, and make future growth dependent on achieving substantial operating improvements or obtaining additional financing.

Theraclion SA (TCLIF) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%70%TCLIF+66.25%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$39.25M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-5.5
Beta (1Y)
0.00
Revenue Growth
-11.09%
EPS Growth
14.45%
Country
US
Employees
36
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Theraclion SA Business Overview & Revenue Model

Company Description

Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a ro...

Theraclion SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TCLIF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALIKOFR:ALIKO45NeutralEUR 22.74M-5.27-22.49%―37.28%7.83%
FR:ALNOVFR:ALNOV45NeutralEUR 31.94M-0.77-159.70%―10.36%29.41%
FR:ALMDTFR:ALMDT43NeutralEUR 207.80M-3.45271.64%―2.16%-5.26%
FR:ALMKTFR:ALMKT40UnderperformEUR 17.50M1.42-157.72%―3.38%―

* Healthcare Sector Average

Performance Comparison

0%50%100%150%TCLIFFR:ALMKTFR:ALNOVFR:ALDMSFR:ALIKOFR:ALMDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TCLIF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TCLIFTheraclion SA0.530.2166.25%
FR:ALMKTMAUNA KEA TECHNOLOGIES0.090.0119.18%
FR:ALNOVNovacyt S.A.0.42-0.01-1.16%
FR:ALDMSDiagnostic Medical Systems0.89-0.33-26.89%
FR:ALIKOIkonisys SA1.540.1410.00%
FR:ALMDTMedian Technologies4.001.0033.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.